GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL: a randomised controlled trial

Trial Profile

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL: a randomised controlled trial

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms GALACTIC version 1.0
  • Most Recent Events

    • 28 Dec 2017 Status changed from active, no longer recruiting to discontinued according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n= 29) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Jul 2017 Trial design published in the Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top